Abstract
Background
In Japan, chemotherapeutic agents that have been approved for the treatment of esophageal cancer include cisplatin, nedaplatin, 5-fluorouracil, vindesine, and docetaxel. We retrospectively investigated the efficacy and toxicity of a combination of nedaplatin plus vindesine, or docetaxel alone, for patients with unresectable or recurrent squamous cell carcinoma of the esophagus refractory to prior chemotherapy with 5-fluorouracil plus platinum.
Methods
Nedaplatin was administered at 90 mg/m2 intravenously on day 1, and vindesine was administered at 3 mg/m2 intravenously on days 1 and 8 every 28 days. Docetaxel 60 mg/m2 or 70 mg/m2 was administered intravenously every 21 days. We analyzed the response rate, overall survival time, progression-free survival time, and toxicity in 24 patients treated with nedaplatin plus vindesine and 28 patients treated with docetaxel.
Results
In patients treated with nedaplatin plus vindesine, the response rate of the 13 patients with measurable lesions was 8% (1/13), the median progression-free survival time was 1.8 months, and the median survival time was 5.5 months. In patients treated with docetaxel, the response rate of the 17 patients with measurable lesions was 18% (3/17), the median progression-free survival time was 2.1 months, and the median survival time was 5.1 months. The most frequent toxicity was neutropenia (grade 4; 13% in the group with nedaplatin plus vindesine and 50% in the docetaxel group), and febrile neutropenia (grade 3; 4% and 18%, respectively).
Conclusion
The efficacy of the two regimens for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum was unsatisfactory. New, more effective therapies are needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Foundation for Promotion of Cancer Research, Editorial Board (2001) Cancer statistics in Japan. National Cancer Center, Tokyo
Foundation for Promotion of Cancer Research, Editorial Board (2003) Cancer statistics in Japan. National Cancer Center, Tokyo
Ohtsu A, Boku N, Muro K, et al. (1999) Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17:2915–2921
Hironaka S, Ohtsu A, Boku N, et al. (2003) Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2–3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 57:425–433
Iizuka T, Kakegawa T, Ide H, et al. (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172–176
Hayashi K, Ando N, Watanabe H, et al. (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31:419–423
Taguchi T, Wakui A, Nabeya K, et al. (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group (in Japanese). Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 19:483–488
Iizuka T, Kakegawa T, Ide H, et al. (1989) A phase II study of vindesine in the treatment of esophageal carcinoma. Jpn J Clin Oncol 19:380–383
Muro K, Hamaguchi T, Ohtsu A, et al. (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955–959
Assersohn L, Brown G, Cunningham D, et al. (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 15:64–69
Lorenzen S, Duyster J, Lersch C, et al. (2005) Capecitabine plus docetaxel every 3 weeks in first-and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 12:2129–2133
Adelstein, DJ, Rybicki LA, Carroll MA, et al. (2005) Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. ASCO Annual Meeting Proceeding: Abstract 4054
Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. (2006) Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24:1612–1619
Tew WP, Shah M, Schwartz G, et al. (2005) Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Gastrointestinal Cancers Symposium: Abstract 5
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yamazaki, K., Hironaka, S., Boku, N. et al. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum. Int J Clin Oncol 13, 150–155 (2008). https://doi.org/10.1007/s10147-007-0738-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-007-0738-y